Results 161 to 170 of about 143,935 (260)

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

open access: yesAndrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick   +7 more
wiley   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz   +17 more
wiley   +1 more source

Variation in Stabilization and Resuscitation Practices at Birth of Preterm Infants Among 12 National or Regional Neonatal Networks

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim Neonatal resuscitation follows national or regional guidelines, but uptake varies in clinical practice. This study aimed to examine variations in reported delivery room practices for infants < 29 weeks' gestation across neonatal units in 12 networks of the International Network for Evaluating Outcomes in Neonates.
Maria Fernanda de Almeida   +676 more
wiley   +1 more source

A real‐world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation

open access: yesBritish Journal of Haematology, EarlyView.
Early letermovir initiation (day 0) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) reduced early cytomegalovirus (CMV) infection and delayed first CMV DNAemia compared with later starts. Extending prophylaxis to 200 days virtually eliminated late CMV reactivation and improved 1‐year overall survival, with no grade ≥3 drug‐related
Shiyu Chen   +4 more
wiley   +1 more source

DHX15 affects AML1‐ETO9a splicing together with HNRNPL, RBM33 in AML1‐ETO‐positive acute myeloid leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Moderate DHX15, HNRNPL and RBM33 expression drives predominant AML1‐ETO mRNA production, while elevated expression of them promotes generating more AE9a mRNA (Aspartic acid ‐ Glutamic acid ‐ Alanine ‐ Aspartic acid sequence)(messenger ribonucleic acid).
Qiao Liu   +13 more
wiley   +1 more source

Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience

open access: yesBritish Journal of Haematology, EarlyView.
In FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty‐two per cent of patients treated with intention‐to‐transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain
Wei Yee Chan   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy